MDM2 promotes ubiquitination and degradation of MDMX

Molecular and Cellular Biology

Volumn 23, Issue 15, 2003, Pages 5113-5121

  Pan, Yu ^a   Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; DNA; LIGASE; PROTEASOME; PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CHEMICAL REACTION; CORRELATION ANALYSIS; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; VIRUS INFECTION; VIRUS RECOMBINANT;

AMINO ACID SEQUENCE; APOPTOSIS; BLOTTING, WESTERN; CYSTEINE ENDOPEPTIDASES; DNA DAMAGE; DOWN-REGULATION; EPITOPES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PLASMIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

ADENOVIRIDAE;

EID: 0042592947     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.15.5113-5121.2003     Document Type: Article

References (33)

1. Chen, J., J. Lin, and A. J. Levine. 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:142-152.
2. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
3. Chen, L., V. Marechal, J. Moreau, A. J. Levine, and J. Chen. 1997. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 272:22966-22973.
4. Fang, S., J. P. Jensen, R. L. Ludwig, K. H. Vousden, and A. M. Weissman. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:8945-8951.
5. Finch, R. A., D. B. Donoviel, D. Potter, M. Shi, A. Fan, D. D. Freed, C. Y. Wang, B. P. Zambrowicz, R. Ramirez-Solis, A. T. Sands, and N. Zhang. 2002. Mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62:3221-3225.
6. Gentiletti, F., F. Mancini, M. D'Angelo, A. Sacchi, A. Pontecorvi, A. G. Jochemsen, and F. Moretti. 2002. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene 21:867-877.
7. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89:5547-5551.
8. Gu, J., H. Kawai, L. Nie, H. Kitao, D. Wiederschain, A. G. Jochemsen, J. Parant, G. Lozano, and Z. M. Yuan. 2002. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277:19251-19254.
9. Jackson, M. W., and S. J. Berberich. 2000. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20:1001-1007.
10. Jackson, M. W., M. S. Lindstrom, and S. J. Berberich. 2002. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 276:25336-25341.
11. Joazeiro, C. A., and A. M. Weissman. 2002. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549-552.
12. Legube, G., L. K. Linares, C. Lemercier, M. Scheffner, S. Khochbin, and D. Trouche. 2002. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 21:1704-1712.
13. Li, C., C. Lihong, and C. Jiandong. 2002. DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol. Cell. Biol. 22:7562-7571.
14. Lin, H. K., L. Wang, Y. C. Hu, S. Altuwaijri, and C. Chang. 2002. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21:4037-4048.
15. Lu, W., J. Lin, and J. Chen. 2002. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res. 62:1305-1310.
16. McMasters, K. M., R. Montes de Oca Luna, J. R. Pena, and G. Lozano. 1996. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13:1731-1736.
17. Midgley, C. A., J. M. Desterro, M. K. Saville, S. Howard, A. Sparks, R. T. Hay, and D. P. Lane. 2001. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19:2312-2323.
18. Migliorini, D., D. Danovi, E. Colombo, R. Carbone, P. G. Pelicci, and J. C. Marine. 2002. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J. Biol. Chem. 277:7318-7323.
19. Migliorini, D., E. L. Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P. G. Pelicci, and J. C. Marine. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22:5527-5538.
20. Oca Luna, R. M., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
21. Parant, J., A. Chavez-Reyes, N. A. Little, W. Yan, V. Reinke, A. G. Jochemsen, and G. Lozano. 2002. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92-95.
22. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126.
23. Ramos, Y. F., R. Stad, J. Attema, L. T. Peltenburg, A. J. van der Eb, and A. G. Jochemsen. 2002. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 61:1839-1842.
24. Ries, S. J., C. H. Brandts, A. S. Chung, C. H. Biederer, B. C. Hann, E. M. Lipner, F. McCormick, and W. M. Korn. 2001. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6:1128-1133.
25. Sengupta, S., and B. Wasylyk. 2002. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15:2367-2380.
26. Sharp, D. A., S. A. Kratowicz, M. J. Sank, and D. L. George. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:38189-38196.
27. Shenoy, S. K., P. H. McDonald, T. A. Kohout, and R. J. Lefkowitz. 2002. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294:1307-1313.
28. Shvarts, A., W. T. Steegenga, N. Riteco, T. van Larr, P. Dekker, M. Bazuine, R. C. A. van Ham, W. V. D. H. van Oordt, G. Hateboer, A. J. van der Eb, and A. G. Jochemsen. 1996. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15:5349-5357.
29. Stad, R., N. A. Little, D. P. Xirodimas, R. Frenk, A. J. van der Eb, D. P. Lane, M. K. Saville, and A. G. Jochemsen. 2001. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2:1029-1034.
30. Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
31. Xirodimas, D., M. K. Saville, C. Edling, D. P. Lane, and S. Lain. 2002. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 20:4972-4983.
32. Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3:579-591.
33. Zhang, Y., and Y. Xiong. 2001. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12:175-186.